Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension -- IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 -- BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics t...
Texas Capital Bancshares, Inc. Announces Third Quarter 2024 Results Record level of income in fee areas of focus(1) Quarterly strategic actions include acquisition of $332 million commercial loan portfolio and balance sheet repositioning of the proceeds from $1.2 billion sale of lower-yielding available-for-sale securities into higher yielding securities Book Value and Tangible Book Value(2) per share both increased 14% year over year, reaching record levels Capital ratios continue to be strong, including 11.2% CET1 and 15.2% Total Capital DALLAS, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tex...
Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension -- Aggregate investment of up to approximately $275 Million by healthcare-focused investment funds, led by Soleus Capital -- BOSTON and ATLANTA, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of cardiopulmonary and neurodegene...
Texas Capital Bancshares, Inc. Announces Date for Q3 2024 Operating Results DALLAS, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2024 before market on Thursday, October 17, 2024. Executive management will host a conference call and webcast to discuss third quarter 2024 operating results on Thursday, October 17, 2024, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number to ...
Texas Capital Launches Government Money Market Exchange Traded Fund First-of-its-kind Money Market ETF to trade under the ticker MMKT DALLAS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bank Private Wealth Advisors, a subsidiary of Texas Capital Bank, and the Texas Capital Funds Trust today announced the launch of the Texas Capital Government Money Market ETF (NYSE: MMKT) (the “MMKT ETF” or “Fund”). This innovative and first-of-its-kind ETF will hold highly liquid, short-term U.S. government debt instruments and cash equivalents, providing an exchange-traded investment option for i...
Texas Capital Bancshares, Inc. Shares Strategic Business Update Three years into its enterprise-wide transformation, firm reports significant progress towards financial and strategic targets DALLAS, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc., the parent company of Texas Capital, led by President & CEO, Rob C. Holmes, today announced a series of actions that materially progresses the firm towards realization of the performance targets outlined in its strategic plan, communicated on . “Three years after announcing our strategic plan, we are pleased with the tre...
Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity Company to host conference call on August 15, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today reported financial results for the second quarter ended June 30, 2024 a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.